echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > PD-1/TIGIT bispecific antibody enters clinical joint development by Cinda and Eli Lilly

    PD-1/TIGIT bispecific antibody enters clinical joint development by Cinda and Eli Lilly

    • Last Update: 2021-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 25, 2021, Innovent Biologics announced that in patients with advanced malignant tumors, its phase 1a clinical trial of the anti-PD-1/TIGIT bispecific antibody IBI321 has completed the first patient administration


    IBI321 is a PD-1/TIGIT bispecific antibody jointly developed by Cinda Biologicals and Eli Lilly and Company, and is developed in China by Cinda Biologicals


    The results of various preclinical studies have shown that IBI321 retains the pharmacodynamic activity of PD-1 inhibitors, and at the same time inhibits the signal of TIGIT, and synergistically enhances the efficacy


    Note: The original text has been deleted

    Reference materials:

    [1] Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.